STOK Stoke Therapeutics
- 11.755
- -0.655-5.28%
Stoke Therapeutics News
Stoke Therapeutics Chief Financial Officer Stephen Tulipano Resigns
By Colin Kellaher Stoke Therapeutics on Monday said its chief financial officer, Stephen Tulipano, has resigned, effective May 7. The Bedford, Mass., biotechnology company said Thomas Leggett, who m
Stoke Therapeutics Appoints CFO
Stoke Therapeutics Appoints Thomas Leggett As Chief Financial Officer >STOK
Stoke Therapeutics Appoints Thomas Leggett As Chief Financial Officer >STOK
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
– Mr. Leggett brings more than two decades of experience as an investment banker and corporate executive leading financial strategy and operations for life science companies – BEDFORD, Mass.--(BUSINES
Garry Menzel Joins GHO Capital as Operating Partner
Garry Menzel joins GHO Capital as Operating Partner Former CEO of TCR2 Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering
Form 144 | Stoke Therapeutics(STOK.US) Insider Proposes to Sell 41.76 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 17, $Stoke Therapeutics(STOK.US)$ Insider Ezbon International Limited intends to sell 3.6 million shares of its common stock on Apr 17, with a total market value of approxi
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK
Buy Rating Justified by Stoke Therapeutics' Promising Pipeline and Strategic Market Positioning
Express News | Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC (GB:HLN) and Stoke Therapeutics (STOK)
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOrgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increas
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
6 analysts have expressed a variety of opinions on Stoke Therapeutics (NASDAQ:STOK) over the past quarter, offering a diverse set of opinions from bullish to bearish.Summarizing their recent assessmen
Express News | Cantor Fitzgerald Reiterates Overweight on Stoke Therapeutics
Stoke Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 — Cantor Fitzgerald Reiterates → Overweight 03/26/2024 29.18% Wedbush $13 → $17 Maintains Outp
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 4, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein
Stoke Therapeutics(STOK.US) Officer Sells US$124.68K in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Ticho Barry sold 9,426 shares of Common Stock on Apr 1, 2024 at an average price of $13.2277 for a total value of $124.68K.Source: Announcement What is statement
Stoke Therapeutics(STOK.US) Officer Sells US$811.21K in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Nash Huw M. sold 61,329 shares of Common Stock on Apr 1, 2024 at an average price of $13.2272 for a total value of $811.21K.Source: Announcement What is statement
Stoke Therapeutics(STOK.US) Officer Sells US$67,667.91 in Common Stock
$Stoke Therapeutics(STOK.US)$ Officer Allan Jonathan sold 5,126 shares of Common Stock on Mar 28, 2024 at an average price of $13.2009 for a total value of $67,667.91.Source: Announcement What is stat
Form 144 | Stoke Therapeutics(STOK.US) Officer Proposes to Sell 827.94K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Stoke Therapeutics(STOK.US)$ Officer HUW MICHAEL NASH intends to sell 61,329 shares of its common stock on Apr 1, with a total market value of approximately $827.94K.
Analysis
Price Target
No Data
